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ABSTRACT
Study queStion
What are the long term trends in the total (live births, 
fetal deaths, and terminations of pregnancy for fetal 
anomaly) and live birth prevalence of neural tube 
defects (NTD) in Europe, where many countries have 
issued recommendations for folic acid 
supplementation but a policy for mandatory folic acid 
fortification of food does not exist?
MethodS
This was a population based, observational study 
using data on 11 353 cases of NTD not associated with 
chromosomal anomalies, including 4162 cases of 
anencephaly and 5776 cases of spina bifida from 28 
EUROCAT (European Surveillance of Congenital 
Anomalies) registries covering approximately 12.5 
million births in 19 countries between 1991 and 2011. 
The main outcome measures were total and live birth 
prevalence of NTD, as well as anencephaly and spina 
bifida, with time trends analysed using random effects 
Poisson regression models to account for 
heterogeneities across registries and splines to model 
non-linear time trends.
SuMMary anSwer and liMitationS
Overall, the pooled total prevalence of NTD during the 
study period was 9.1 per 10 000 births. Prevalence of 
NTD fluctuated slightly but without an obvious 
downward trend, with the final estimate of the pooled 
total prevalence of NTD in 2011 similar to that in 1991. 
Estimates from Poisson models that took registry 
heterogeneities into account showed an annual 
increase of 4% (prevalence ratio 1.04, 95% confidence 
interval 1.01 to 1.07) in 1995-99 and a decrease of 3% 
per year in 1999-2003 (0.97, 0.95 to 0.99), with stable 
rates thereafter. The trend patterns for anencephaly 
and spina bifida were similar, but neither anomaly 
decreased substantially over time. The live birth 
prevalence of NTD generally decreased, especially for 
anencephaly. Registration problems or other data 
artefacts cannot be excluded as a partial explanation 
of the observed trends (or lack thereof) in the 
prevalence of NTD.
what thiS Study addS
In the absence of mandatory fortification, the 
prevalence of NTD has not decreased in Europe despite 
longstanding recommendations aimed at promoting 
peri-conceptional folic acid supplementation and 
existence of voluntary folic acid fortification.
Funding, CoMpeting intereStS, data Sharing
The study was funded by the European Public Health 
Commission, EUROCAT Joint Action 2011-2013. HD and 
ML received support from the European Commission 
DG Sanco during the conduct of this study. No 
additional data available.
Introduction
Neural tube defects (NTD) are a major group of severe 
congenital anomalies that are associated with substan-
tial mortality, morbidity, and long term disability, as 
well as emotional, psychological, and economic costs.1 2 
Each year, approximately 5000 fetuses in Europe are 
affected with NTD. Most of these cases are diagnosed 
prenatally, and termination of pregnancy for fetal 
anomaly is by far the most common outcome for fetuses 
with NTD.3-5
Convincing evidence shows that peri-conceptional 
folic acid supplementation can substantially decrease 
the prevalence of NTD.6-8  Whereas many countries in 
Europe have issued recommendations for folic acid 
supplementation for women of reproductive age, or 
specifically for those who intend to become pregnant, 
mandatory fortification programmes do not yet exist in 
Europe.9  A previous study found that in the past these 
recommendations had not had an appreciable effect on 
the prevalence of NTD in European countries.10  A more 
WhAT IS AlReAdy knoWn on ThIS TopIC
Peri-conceptional supplementation with folic acid can greatly reduce the risk of 
neural tube defects (NTD)
Although various recommendations for folic acid supplementation have been 
issued in Europe and elsewhere, important barriers exist for effective 
implementation of these recommendations
In contrast, mandatory fortification of food staples with folic acid has proved very 
effective in decreasing the prevalence of NTD
Up to date, population based data on the long term trends of the prevalence of NTD 
in Europe, where policies for mandatory fortification do not exist, are not available 
and could help to inform future policies
WhAT ThIS STudy AddS
The prevalence of NTD has not decreased in Europe despite longstanding 
recommendations aimed at promoting peri-conceptional folic acid 
supplementation and the existence of voluntary folic acid fortification
Policies for mandatory fortification of food staples with folic acid should be 
considered as an important and more effective means for prevention of NTD in Europe
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recent but preliminary analysis of the pooled data on 
the prevalence of NTD in the European Surveillance of 
Congenital Anomalies (EUROCAT) network suggested 
that their overall prevalence may have slightly 
decreased in the period 2004-08.5
 Most population based congenital anomaly regis-
tries in Europe belong to the EUROCAT network (www.
eurocat-network.eu/), with a common database. In 
2009 EUROCAT published a special report on NTD,9 
which showed that important barriers continue to exist 
for successful implementation of the recommendations 
for folic acid supplementation. Hence, only a small 
minority of women take folic acid supplements in the 
peri-conceptional period as recommended.11 12
In this study, we assessed the trends in the total prev-
alence and live birth prevalence of NTD in Europe by 
using data from EUROCAT registries for the period 1991-
2011. We examined trends for all NTD combined, as well 
as separately for anencephaly and spina bifida, the 
most common forms of NTD.
Methods
data sources
Since 1980, the EUROCAT central database has held 
individual anonymised records of cases of congenital 
anomaly occurring for full member registries and aggre-
gate data for associate member registries, including live 
births, fetal deaths from 20 weeks gestational age, and 
termination of pregnancy for fetal anomaly. Informa-
tion on each of the registries, including methods of case 
ascertainment and local procedures regarding ethics 
approval for the registries’ activities and their collabo-
rations with EUROCAT, are available on the EUROCAT 
website (www.eurocat-network.eu/ABOUTUS/Member-
Registries/MembersAndRegistryDescriptions/AllMem-
bers) and in the publication by Greenlees et al.13 All 
registries use ICD-9 (international classification of dis-
eases, 9th revision) or ICD-10 with BPA extension to 
code up to nine syndrome or malformation codes for 
each case.
All cases that were not associated with a chromo-
somal anomaly and had a diagnostic code correspond-
ing to a neural tube defect (ICD-9 740 -742 and ICD-10 
Q00, Q01, Q05) were included for full and associate 
EUROCAT registries that could provide data from both 
the 1990s and the 2000s; most registries provided data 
for the entire, or almost the entire, time period between 
1991 and 2011 (table 1). We extracted data on 11 353 cases 
of NTD, including 4162 cases of anencephaly (ICD-9 740 
and ICD-10 Q00), 5776 cases of spina bifida (ICD-9 741 
and ICD-10 Q05), and 1415 cases of encephalocele (ICD-9 
7420 and ICD-10 Q01), from 28 registries in 19 countries 
covering approximately 12.5 million births, in October 
2013 for the analysis of time trends in total and live birth 
prevalence of NTD between 1991 and 2011.
patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures; nor were they involved in 
design and implementation of the study. There are no 
plans to involve patients in dissemination.
data analysis
We plotted the time trends, during the period 1991 to 
2011, in the total and live birth prevalence of all 
non-chromosomal NTD and separately for anencephaly 
and spina bifida. We defined total prevalence of NTD as 
the total number of cases of NTD (live births plus fetal 
deaths after 20 weeks of gestational age plus termina-
tion of pregnancy for fetal anomaly) per 10 000 total 
births (live births plus fetal deaths). We defined live 
birth prevalence as the number of live births with NTD 
per 10 000 live births. We examined the plots of time 
trends in total and live birth prevalence of NTD by using 
restricted cubic splines,14 15 which can provide a flexi-
ble, semi-parametric, continuous model of the relation 
between prevalence of NTD and time.
Using the number of births as the “exposure” vari-
able, we then used random effects Poisson regression 
models to examine the annual trends in the prevalence 
of NTD, for all NTD combined and separately for anen-
cephaly and spina bifida. We used random effects mod-
els to take into account any heterogeneity that may exist 
across the registries.16 17 In the Poisson models, we used 
linear splines (or “piece-wise exponential models”) for 
modelling the time trends in the prevalence of NTD; we 
used splines with five equally spaced knots based on 
the quintiles of the distribution of the time period to 
estimate separately the annual trends for the following 
time periods: 1991-95, 1995-99, 1999-2003, 2003-07, and 
2007-11. We used Stata software (versions 11 and 13) for 
all analyses.
Results
trends in total prevalence of ntd
Figure 1  shows the time trend in the total prevalence of 
non-chromosomal NTD for the period 1991-2011, using 
pooled data from all of the EUROCAT registries included 
in the study and with time trends modelled with 
restricted cubic splines. The total prevalence of NTD 
was 9.1 (95% confidence interval 8.9 to 9.3) per 10 000 
for 1991-2011 (table 1 ), fluctuating between a maximum 
of approximately 10.1 (highest) per 10 000 in the period 
1999-2003 and 8.5 (lowest) per 10 000 in the period 
2003-07 (fig 1). Overall, the total prevalence of NTD in 
2011 was comparable to that in 1991. Time trend pat-
terns in the pooled prevalence of anencephaly and 
spina bifida were comparable to those for all NTD com-
bined.
Table 2 shows the results of random effects Poisson 
regression models that take into account heterogene-
ities across registries in estimating the time trends. Esti-
mates are presented as prevalence ratios and can be 
interpreted as percentage increase (for ratios >1) or per-
centage decrease (for ratios <1). The estimates suggest 
that the total prevalence of NTD increased by about 4% 
a year between 1995 and 1999 (prevalence ratio 1.04, 
95% confidence interval 1.01 to 1.07), decreased by 3% 
in 1999-2003 (0.97, 0.95 to 0.99), and was fairly stable 
thereafter.
For non-chromosomal anencephaly, a slight increase 
was apparent in the 1990s, which was offset by a 4% 
decrease between 2003 and 2007 (prevalence ratio 0.96, 
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0.93 to 0.99), with stable rates afterwards until 2011. For 
non-chromosomal spina bifida, trends in the total preva-
lence mirrored those for overall NTD noted above (table 2).
trends in live birth prevalence of ntd
Live birth prevalence of NTD was less than half of all 
cases of NTD and decreased substantially over the study 
period (fig 2 ). Estimates from the random effects Poisson 
models suggested that the decrease occurred more 
during the 1990s (table 2), once heterogeneities across 
registries were taken into account. Estimates from the 
random effects Poisson models also suggested that 
trends in live birth prevalence of spina bifida were simi-
lar to those for all NTD, whereas for anencephaly greater 
decreases were seen in the live birth prevalence, includ-
ing a large decrease in the most recent period of 2007-11 
equivalent to a 13% annual decrease (prevalence ratio 
0.87, 0.76 to 1.00), compared with a stable total preva-
lence of anencephaly during the same period.
discussion
Using data for more than 11 000 cases of non-chromo-
somal neural tube defects from 28 population based 
table 2 | random effects poisson regression models with splines (piece-wise exponential 
models) of trends in total and live birth prevalence of non-chromosomal neural tube 
defects, anencephaly, and spina bifida in 28 member registries in euroCat, 1991-2011
time period
total prevalence live birth prevalence
annual prevalence 
ratio (95% Ci) p value*
annual prevalence 
ratio (95% Ci) p value*
all neural tube defects
1991-95 0.98 (0.95 to 1.02)
<0.001
0.93 (0.88 to 0.98)
<0.001
1995-99 1.04 (1.01 to 1.07) 0.97 (0.93 to 1.01)
1999-2003 0.97 (0.95 to 0.99) 0.96 (0.93 to 1.00)
2003-07 0.99 (0.97 to 1.01) 0.97 (0.93 to 1.00)
2007-11 0.99 (0.97 to 1.01) 0.98 (0.93 to 1.02)
anencephaly
1991-95 1.01 (0.95 to 1.07)
<0.001
0.93 (0.80 to 1.09)
<0.001
1995-99 1.03 (0.99 to 1.08) 1.00 (0.89 to 1.13)
1999-2003 0.98 (0.95 to 1.02) 0.91 (0.82 to 1.00)
2003-07 0.96 (0.93 to 0.99) 0.99 (0.89 to 1.09)
2007-11 1.01 (0.98 to 1.05) 0.87 (0.76 to 1.00)
Spina bifida
1991-95 0.97 (0.92 to 1.02)
<0.001
0.94 (0.88 to 1.00)
<0.001
1995-99 1.04 (1.00 to 1.07) 0.96 (0.92 to 1.01)
1999-2003 0.97 (0.94 to 1.00) 0.97 (0.93 to 1.01)
2003-07 0.99 (0.96 to 1.01) 0.96 (0.93 to 1.00)
2007-11 0.99 (0.96 to 1.03) 1.00 (0.95 to 1.05)
*P value tests statistical significance of any trend. In this case, significant P values indicate statistically 
significant non-monotonic trend for total prevalence and downward trend for live birth prevalence of neural tube 
defects, anencephaly, and spina bifida.
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Fig 2 | trends in live birth prevalence of non-chromosomal 
neural tube defects in europe, 1991-2011: restrictive cubic 
spline estimates of pooled data in euroCat registries
Fig 1 | trends in total 
prevalence of non-
chromosomal neural tube 
defects in europe, 
1991-2011: restrictive cubic 
spline estimates of pooled 
data in euroCat registries
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registries in 18 countries covering approximately 12.5 
million births in Europe over the period 1991 to 2011, we 
found that the overall (pooled) total prevalence of NTD 
in 2011 was fairly similar to that in 1991 (~9 per 10 000 
births). This was also true for the two main types of 
NTD, anencephaly and spina bifida, each of which 
accounts for approximately half of the cases of NTD. 
Whereas estimates from mixed models that took into 
account heterogeneities across registries suggested that 
a small decrease (~3% per year) in total prevalence of 
NTD between 1999 and 2003, this decrease followed a 
period of a comparable increase between 1995 and 1999. 
Overall, we found no clear evidence of a downward 
trend over the 20 year study period. In contrast, as a 
result of prenatal diagnosis and termination of preg-
nancy for fetal anomaly of most NTD in Europe, their 
live birth prevalence substantially decreased over time, 
especially for anencephaly.
Strengths and limitations of study
This was a large study looking at long term trends in the 
prevalence of NTD based on data from a number of pop-
ulation based registries in Europe. We took into account 
heterogeneities across registries by using random 
effects models. Nevertheless, we cannot exclude the 
possibility that registration problems or other data arte-
facts may be a partial explanation of the observed 
trends (or lack thereof) in the prevalence of NTD. How-
ever, we had no a priori reason to believe that any 
changes in registrations would have occurred in spe-
cific periods of time in a way that would explain the 
observed, long term time trends in our study.
Comparisons with other studies
Our results are consistent with those of an older study 
of trends in the prevalence of NTD in Europe.10  The 
overall long term fluctuations in the total prevalence of 
NTD in our data cannot be due to mandatory fortifica-
tion of food staples, as such a policy has not yet been 
implemented in European countries.9  Voluntary fortifi-
cation or the various recommendations issued for folic 
acid supplementation for women of reproductive age in 
European countries may have had an effect,9 18 19  even if 
small and as yet very little documented, on the intake of 
folic acid and thereby the prevalence of NTD.9 12 18  How-
ever, the available evidence points to very low uptake of 
folic acid supplementation in European countries.11 12
In any case, this was an ecological study and, even if 
folic acid is known to be an important factor for 
explaining trends in NTD, it is not the only possible 
reason for any changes in NTD over time. Changes in 
other risk factors of NTD (for example, maternal smok-
ing)20-22  and changes in the incidence and manage-
ment of maternal chronic health conditions, such as 
obesity, diabetes, and epilepsy, or psychiatric illnesses 
treated with anti-epileptic drugs that are known to be 
associated with a higher risk of NTD,23-25  as well as any 
changes in population characteristics (for example, 
owing to immigration),2 must also be considered as 
possible explanations for the observed fluctuations in 
the prevalence of NTD.
Conclusions and policy implications
Our results underscore the fact that 20 years after pub-
lication of the Medical Research Council study,6 which 
provided definitive evidence for the efficacy of folic acid 
in preventing NTD, and years after various recommen-
dations have been issued to promote folic acid supple-
mentation to ensure adequate peri-conceptional folate 
concentrations for pregnant women, Europe has failed 
to implement an effective policy for prevention of NTD 
by folic acid.
NTD represent one of the most prevalent group of 
birth defects with serious consequences for newborns 
and their families. Although termination of pregnancy 
for fetal anomaly has considerably reduced the live 
birth prevalence of these anomalies, it is certainly not 
an optimal solution for a birth defect that is highly pre-
ventable with a readily available and low cost measure, 
as is the case for NTD with folic acid supplementation 
or food fortification. Consumption of adequate natural 
folates should also be encouraged but in many coun-
tries will not raise folate concentrations sufficiently and 
is likely to leave vulnerable populations unprotected.
Our data suggest that recommendations, voluntary 
fortification, or both have not been effective in decreas-
ing the prevalence of NTD in Europe. Hence, policies for 
mandatory fortification of food staples with folic acid 
should be considered as an important and more effec-
tive means for prevention of NTD,8 26 27  while weighing 
the evidence for its proven benefits and possible 
risks.2  19
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